Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention
NCT00285857
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
30
Enrollment
OTHER
Sponsor class
Stopped
Slow accrual
Conditions
Breast Cancer
Interventions
DRUG:
Lovastatin
Sponsor
Stanford University